Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Gains from Sales and Divestitures: 2022-2023

Historic Gains from Sales and Divestitures for Therapeutics (LENZ) over the last 2 years, with Sep 2023 value amounting to $703,035.

  • Therapeutics' Gains from Sales and Divestitures rose 40.00% to $703,035 in Q3 2023 from the same period last year, while for Sep 2023 it was $703,035, marking a year-over-year increase of 40.00%. This contributed to the annual value of $553,443 for FY2022, which is N/A change from last year.
  • As of Q3 2023, Therapeutics' Gains from Sales and Divestitures stood at $703,035, which was up 7.50% from $653,970 recorded in Q2 2023.
  • Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $703,035 during Q3 2023, with a 5-year trough of $398,028 in Q1 2022.
  • Moreover, its 2-year median value for Gains from Sales and Divestitures was $553,443 (2022), whereas its average is $552,207.
  • Data for Therapeutics' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 51.93% (in 2023) over the last 5 years.
  • Over the past 2 years, Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $553,443 in 2022, then surged by 40.00% to $703,035 in 2023.
  • Its Gains from Sales and Divestitures stands at $703,035 for Q3 2023, versus $653,970 for Q2 2023 and $604,734 for Q1 2023.